You appear to be using an older version of Internet Explorer. We suggest you upgrade your browser for the best viewing experience. Upgrade to a Modern Browser
Challenging a patentee’s legal entitlement to claim priority is a common tactic in contentious proceedings in Europe. If successful, the patent can be held invalid by the effect of intervening prior art. This situation arose in a recent high-profile case before the Board of Appeal of the European Patent Office in decision T844/18. A high-value patent in the field of gene editing (CRISPR) was revoked for lack novelty over intervening prior art following a loss of priority. The case does not change the law in Europe. Nevertheless, it provides an opportunity to reassess best practice for applicants. In this webinar we will provide a concise review of European case law and practice in this area. We will briefly discuss what went wrong and why for the patentees in T844/18, and we will outline practical steps and measures that can be taken by applicants to help safeguard priority claims in Europe.